Research indicates that administering weight loss injections to eligible individuals could boost the UK economy by £4.5 billion.
It’s estimated that by 2050, over 25 million people, including about 3.8 billion globally and nearly 750 million children and young people, will be classified as overweight or obese. Currently, 26.5% of adults in the UK are considered obese, and around 4.6 million individuals have been diagnosed with type 2 diabetes.
Obesity and type 2 diabetes are projected to cost the UK £100 million annually. Semaglutide, recognized under the brand names Wegovy and Ozempic, is linked to a reduced likelihood of 42 different health conditions, yet its overall effects on quality of life and productivity remain unclear.
A recent study presented at the European Conference on Obesity in Malaga, Spain, analyzed data from 2,660 participants in three separate UK clinical trials involving semaglutide, focusing on individuals with obesity and/or type 2 diabetes. Findings suggest that those using semaglutide could gain an additional five days of employment per job, while also performing up to 12 days of unpaid work, including volunteering and childcare, and consuming less overall.
The researchers calculated these productivity improvements—termed the annual “net production value”—averaging £1,127 per person.
This translates to approximately £4.31 billion in potential annual productivity gains associated with NHS semaglutide, targeting around 4 million eligible type 2 diabetes patients. Semaglutide is advised for individuals with a BMI of at least 35 alongside a related health condition, according to National Institutes of Health guidelines.
Robert King, a senior health economist at Train Clark & Peacock and a co-author of the study, emphasized that the extensive social impacts of weight loss treatments warrant serious consideration.
“While the per capita productivity gains may appear modest, the cumulative effect is significant at the population level. Hence, prioritizing treatment for these chronic conditions is crucial,” he stated.
Naveed Sattar, a professor of psychometabolic medicine at the University of Glasgow, noted that the potential social advantages of weight loss medications extend well beyond medical implications. However, he cautioned that the high expense of these drugs means they are currently unaffordable for widespread use.
“At this point, we can’t afford to treat everyone who stands to benefit, so we must focus on those who are most in need and most likely to gain health benefits,” Sattar remarked.
Health Secretary Wes Street commented, “These medications could significantly impact our efforts to combat obesity and reintegrate unemployed Britons into the workforce. We will thoroughly evaluate the findings of this important study.”
